Related Experiment Videos
Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma
Z Culig1, A Hittmair, A Hobisch
1Department of Urology, University of Innsbruck, Austria.
Background:
Monoclonal antibodies B1 and B3 react with Lewis(y) and related carbohydrate antigens, which are abundant in many solid tumors. These antibodies, when conjugated to a toxin, have been used to target a variety of cancers. Treatment options for advanced prostate cancer are very limited, and there is a need to develop new therapies. In this study, we have asked whether antibodies B1 and B3 react with metastatic lesions from human prostatic carcinoma.
Methods:
Indirect streptavidin-biotin peroxidase immunohistochemistry was performed on formalin-fixed specimens from prostate cancer metastases. A total of 6 lymph node metastatic samples from patients who did not receive endocrine treatment and specimens of 14 distant metastases from patients who failed hormonal therapy were obtained.
Results:
Of the samples, 6 lymph node and 11 distant metastases stained for B1. In the case of B3 staining, 6 lymph node and 10 distant metastatic lesions were positive. In about half of these metastatic samples, more than 40% of cells were immunoreactive with either antibody. Two metastatic samples stained neither for B1 nor for B3 antibody. In general, B1 staining intensity was stronger in samples in which more than 40% of cells were positive.
Conclusions:
Our results suggest that B1 and B3 immunoconjugates could be applied to target a substantial percentage of prostate cancer metastases.
Insights
Monoclonal antibodies B1 and B3 show reactivity with prostate cancer metastases. These findings suggest potential for B1 and B3 immunoconjugates in treating advanced prostate cancer.
Area of Science:
- Oncology
- Immunology
- Carbohydrate Chemistry
Background:
- Monoclonal antibodies B1 and B3 target Lewis(y) antigens found on many solid tumors.
- Antibody-toxin conjugates are explored for cancer therapy.
- Advanced prostate cancer has limited treatment options, necessitating novel approaches.
Purpose of the Study:
- To investigate the reactivity of monoclonal antibodies B1 and B3 with metastatic lesions in human prostate cancer.
- To assess the potential of these antibodies for targeted prostate cancer therapy.
Main Methods:
- Immunohistochemistry was used to analyze formalin-fixed prostate cancer metastasis specimens.
- Samples included lymph node metastases and distant metastases from patients with advanced or hormonally treated prostate cancer.
Main Results:
- Antibody B1 stained 6/6 lymph node and 11/14 distant metastases.
- Antibody B3 stained 6/6 lymph node and 10/14 distant metastases.
- Over 40% of cells showed immunoreactivity in about half of the positive metastatic samples, with stronger intensity for B1.
Conclusions:
- Monoclonal antibodies B1 and B3 demonstrate significant reactivity with prostate cancer metastases.
- B1 and B3 immunoconjugates show promise for targeting a substantial proportion of prostate cancer metastases.